<DOC>
	<DOC>NCT02433236</DOC>
	<brief_summary>Phase 2, multi-center, open label extension study to evaluate 2 dose regimens of fostamatinib in approximately 25 subjects. The study will consist of 11 visits over 15 months.</brief_summary>
	<brief_title>Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis, IGA</mesh_term>
	<criteria>Completed Study C938788050, including having received a posttreatment renal biopsy, and having had a clinically meaningful response (i.e. decreased proteinuria or improved renal histology) Able and willing to give written informed consent Unresolved Grade 2 or greater toxicity in Study C935788050</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>